<span item_type="fundamental" item_id="61aea40524cfd2afa7bf6889100f4acf" counter_id="ST/US/APGE" env="prod"></span><span item_type="announcement" item_id="548221357306808833" env="prod"></span><p>EBIT: As of FY2025 Q2, the actual value is USD -73.17 M, missing the estimate of USD -69.22 M.</p><p></p><h3>Financial Metrics by Segment</h3><h4>Segment Revenue</h4><ul><li>The report does not provide specific segment revenue details.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"></span></li></ul><h4>Operational Metrics</h4><ul><li>The report does not provide specific operational metrics such as net income, gross margin, operating profit, operating margin, or operating costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"></span></li></ul><h4>Cash Flow</h4><ul><li>The report does not provide specific cash flow details.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"></span></li></ul><h4>Unique Metrics</h4><ul><li>The report does not provide any unique company-specific financial indicators.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"></span></li></ul><h4>Outlook / Guidance</h4><ul><li>The report does not include any forward-looking statements or guidance.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm"></span></li></ul><h3>Cash Position</h3><ul><li>As of June 30, 2025, Apogee Therapeutics, Inc. had cash, cash equivalents, and marketable securities totaling $621.2 million, compared to $681.4 million as of March 31, 2025. The company expects these resources to fund operations into the first quarter of 2028.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-ex99_1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses for the quarter ended June 30, 2025, were $55.7 million, up from $33.2 million for the same period in 2024. This increase was primarily due to the development of the APG777 program and increased personnel-related expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-ex99_1.htm"></span></li></ul><h3>General and Administrative (G&amp;A) Expenses</h3><ul><li>G&amp;A expenses were $17.5 million for the quarter ended June 30, 2025, compared to $10.9 million for the same period in 2024. The rise in expenses was mainly due to increased personnel-related expenses and equity-based compensation.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>The net loss for the quarter ended June 30, 2025, was $66.1 million, compared to a net loss of $33.8 million for the same period in 2024. The increase in net loss was primarily due to higher R&amp;D and G&amp;A expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Apogee Therapeutics anticipates that its existing cash resources will support its operations into the first quarter of 2028. The company plans to initiate Phase 3 trials of APG777 in 2026, pending results from ongoing trials and regulatory feedback. Additionally, Apogee expects to announce plans for Phase 2b trials in asthma and eosinophilic esophagitis in 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-ex99_1.htm"></span></li></ul>

Apogee Therapeutic | 8-K: FY2025 Q2 EBIT Misses Estimate at USD -73.17 M